Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,689.10 | 5.50 | -0.06% |
| CAC 40 | 7,981.07 | 27.30 | 0.34% |
| DAX 40 | 23,278.85 | 115.93 | 0.50% |
| Dow JONES (US) | 45,752.26 | 386.51 | -0.84% |
| FTSE 100 | 9,527.65 | 20.24 | 0.21% |
| HKSE | 25,409.64 | 425.93 | -1.65% |
| NASDAQ | 22,078.05 | 486.18 | -2.15% |
| Nikkei 225 | 48,708.47 | 1,115.47 | -2.24% |
| NZX 50 Index | 13,419.40 | 20.00 | -0.15% |
| S&P 500 | 6,538.76 | 103.40 | -1.56% |
| S&P/ASX 200 | 8,418.80 | 2.30 | 0.03% |
| SSE Composite Index | 3,876.58 | 54.47 | -1.39% |